Overview

Study to Assess PK, Safety and Tolerability in Healthy Subjects

Status:
COMPLETED
Trial end date:
2023-12-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
Phase:
PHASE1
Details
Lead Sponsor:
Changzhou Qianhong Bio-pharma Co., Ltd.